Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Learn which fund family offers the best Sharpe ratio indices and why it matters for risk-adjusted performance. Compare funds to identify strong performers.
28,055 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Truth Social’s spot Bitcoin ETF has withdrawn its S-1 filing, signaling tougher market conditions for plain-vanilla c...
Meta Platforms has hovered around a pivotal level. This guide weighs the pros, cons, and real-world steps to decide i...
The SEC has launched a public-comment process on novel ETFs, signaling tighter rules for crypto assets and leverage a...
Green Brick Partners stands out in a tougher housing market thanks to a land-heavy model and strict debt discipline, ...
A federal judge pressed the government over its bid to block Anthropic’s AI from top-secret systems. The hearing unde...
Bitcoin, Ethereum, and XRP led a weekend comeback, lifting the total crypto market cap and centering attention on a p...
Analysts just boosted Crocs stock after recent upgrade rumors and data. This guide breaks down why the upgrade happen...
Dividend income can be a reliable part of a retirement plan. This guide shows the math behind earning $12,000 annuall...
Regulators signal a spring decision to move perpetual Bitcoin futures onto U.S. exchanges. The shift could reshape bi...
SanDisk announced a $1 billion strategic equity investment in Nanya Technology, prompting a roughly 6% share decline ...
A risk disclosure in SpaceX’s pre-IPO paperwork flags space-based warfare threats to Starlink. As investors watch an ...